Aileron Therapeutics - ALRN Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALRN, but not buy additional shares or sell existing shares.
View ALRN analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month price objectives for Aileron Therapeutics' shares. Their ALRN share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 61.1%.
View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts.

Aileron Therapeutics' stock was trading at $0.5629 at the beginning of 2022. Since then, ALRN stock has increased by 356.6% and is now trading at $2.57.
View the best growth stocks for 2022 here.

Aileron Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 12,300 shares, a decrease of 96.2% from the October 31st total of 322,000 shares. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company's stock are short sold.
View Aileron Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ALRN earnings forecast.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its earnings results on Tuesday, November, 1st. The company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.60) by $0.20.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (57.37%), KCK LTD. (0.49%), Renaissance Technologies LLC (4.20%) and Envestnet Asset Management Inc. (0.20%). Insiders that own company stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends.

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALRN stock can currently be purchased for approximately $2.57.

Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $11.67 million. The company earns $-26,160,000.00 in net income (profit) each year or ($6.60) on an earnings per share basis.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com.